Immunostaining of mammary fat pad-derived tumour sections revealed a significant loss (p < 0.01) of all three EMT markers (Fig. 4A) in tumours derived from the Kindlin-2-deficient MDA-MB-231 or 4T1 (Kindlin-2-CRISPR) BC cells compared to their control counterparts (Scram CRISPR). This evidence concerns the gene FERMT2 and breast cancer.